Advertisement

Topics

Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

16:06 EST 8 Nov 2017 | BioPortfolio Report Blog

Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP Pipeline Review, H2 2017


Summary


Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Islet Amyloid Polypeptide Pipeline Review, H2 2017, outlays comprehensive information on the Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP Islet amyloid polypeptide IAPP or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulinstimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Musculoskeletal Disorders and Central Nervous System which include indications Type 2 Diabetes, Obesity, Type 1 Diabetes Juvenile Diabetes, NonAlcoholic Steatohepatitis NASH, Osteoarthritis, Alzheimer's Disease and Non Alcoholic Fatty Liver Disease NAFLD.


Furthermore, this report also reviews key players involved in Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP

The report reviews Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP targeted therapeutics and enlists all their major and minor projects

The report assesses Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Islet Amyloid Polypeptide Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...